Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 8/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802259 | 0.91 | MGLL (0.42) | MGLLSYKTPSAB1ADORA1SPR | |
| SCHEMBL2801629 | 0.90 | MGLL (0.42) | MGLLSYKTPSAB1ADORA1SPR | |
| SCHEMBL2801085 | 0.84 | PDE4B (0.44) | SPRALDH1A1 | |
| SCHEMBL2801711 | 0.84 | DHODH (0.46) | MGLLSYKSPRALDH1A1 | |
| SCHEMBL2802215 | 0.83 | ALDH1A1 (0.42) | SYKSPRALDH1A1 | |
| SCHEMBL2801684 | 0.83 | LMNA (0.45) | MGLLSPRALDH1A1 | |
| SCHEMBL2800955 | 0.83 | SPR (0.41) | MGLLSPRALDH1A1 | |
| SCHEMBL2801767 | 0.82 | SPR (0.47) | MGLLSYKTPSAB1SPRALDH1A1 | |
| SCHEMBL2801102 | 0.82 | SIRT5 (0.50) | MGLLSPRALDH1A1 | |
| SCHEMBL2800506 | 0.82 | KMT2A (0.41) | MGLLSPRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | MGLL 4369/4885SYK 958/4885TPSAB1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.